#BEGIN_DRUGCARD DB01127

# AHFS_Codes:
84:04.08.08

# ATC_Codes:
D01AC03
G01AF05

# Absorption:
After topical application to the skin of normal subjects, systemic absorption of econazole nitrate is extremely low. Although most of the applied drug remains on the skin surface, drug concentrations were found in the stratum corneum which, by far, exceeded the minimum inhibitory concentration for dermatophytes.

# Biotransformation:
Hepatic.

# Brand_Mixtures:
Not Available

# Brand_Names:
Econazole Nitrate
Ecostatin
Ecostatin Vaginal Ovules
Ecostatin cream
Gyno-Pevaryl
Gyno-Pevaryl 150
Ifenec
Palavale
Pevaryl
Spectazole
Spectazole cream

# CAS_Registry_Number:
27220-47-9

# ChEBI_ID:
4754

# Chemical_Formula:
C18H15Cl3N2O

# Chemical_IUPAC_Name:
1-{2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2011948

# Description:
A broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally. [PubChem]

# Dosage_Forms:
Suppository	Intravaginal

# Drug_Category:
Antifungal Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
5.5

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Econazole

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C18H15Cl3N2O/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21/h1-9,12,18H,10-11H2

# InChI_Key:
InChIKey=LEZWWPYKPKIXLL-UHFFFAOYSA-N

# Indication:
For topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by <i>Trichophyton rubrum</i>, <i>Trichophyton mentagrophytes</i>, <i>Trichophyton tonsurans</i>, <i>Microsporum canis</i>, <i>Microsporum audouini</i>, <i>Microsporum gypseum</i>, and <i>Epidermophyton floccosum</i>, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor.

# KEGG_Compound_ID:
C08068

# KEGG_Drug_ID:
D03936

# LIMS_Drug_ID:
1127

# Mechanism_Of_Action:
Econazole interacts with 14-&alpha; demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Econazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
381.684

# Molecular_Weight_Mono:
380.024996233

# Organisms_Affected:
Yeast and other fungi

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/spe1410.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA164746010

# Pharmacology:
Econazole is an antifungal medication related to fluconazole (Diflucan), ketoconazole (Nizoral), itraconazole (Sporanox), and clotrimazole (Lotrimin, Mycelex). Econazole prevents fungal organisms from producing vital substances required for growth and function. This medication is effective only for infections caused by fungal organisms. It will not work for bacterial or viral infections.

# Predicted_LogP_Hydrophobicity:
4.67

# Predicted_LogS:
-5.4

# Predicted_Water_Solubility:
1.48e-03 g/l

# Primary_Accession_No:
DB01127

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
3198

# PubChem_Substance_ID:
46508881

# RxList_Link:
http://www.rxlist.com/cgi/generic3/econazole.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00943

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Overdosage of econazole in humans has not been reported to date. In mice, rats guinea pigs and dogs, the oral LD 50 values were found to be 462, 668, 272, and > 160 mg/kg, respectively.

# Update_Date:
2013-02-08 16:19:56 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Econazole

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP19A1

# Phase_1_Metabolizing_Enzyme_1_ID:
3811

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 19A1

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 19A1
MVLEMLNPIHYNITSIVPEAMPAATMPVLLLTGLFLLVWNYEGTSSIPGPGYCMGIGPLI
SHGRFLWMGIGSACNYYNRVYGEFMRVWISGEETLIISKSSSMFHIMKHNHYSSRFGSKL
GLQCIGMHEKGIIFNNNPELWKTTRPFFMKALSGPGLVRMVTVCAESLKTHLDRLEEVTN
ESGYVDVLTLLRRVMLDTSNTLFLRIPLDESAIVVKIQGYFDAWQALLIKPDIFFKISWL
YKKYEKSVKDLKDAIEVLIAEKRRRISTEEKLEECMDFATELILAEKRGDLTRENVNQCI
LEMLIAAPDTMSVSLFFMLFLIAKHPNVEEAIIKEIQTVIGERDIKIDDIQKLKVMENFI
YESMRYQPVVDLVMRKALEDDVIDGYPVKKGTNIILNIGRMHRLEFFPKPNEFTLENFAK
NVPYRYFQPFGFGPRGCAGKYIAMVMMKAILVTLLRRFHVKTLQGQCVESIQKIHDLSLH
PDETKNMLEMIFTPRNSDRCLEH

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P11511

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_2_ID:
4512

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP2E1

# Phase_1_Metabolizing_Enzyme_3_ID:
6013

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 2E1

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 2E1
MSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLELKNIPKSFTRL
AQRFGPVFTLYVGSQRMVVMHGYKAVKEALLDYKDEFSGRGDLPAFHAHRDRGIIFNNGP
TWKDIRRFSLTTLRNYGMGKQGNESRIQREAHFLLEALRKTQGQPFDPTFLIGCAPCNVI
ADILFRKHFDYNDEKFLRLMYLFNENFHLLSTPWLQLYNNFPSFLHYLPGSHRKVIKNVA
EVKEYVSERVKEHHQSLDPNCPRDLTDCLLVEMEKEKHSAERLYTMDGITVTVADLFFAG
TETTSTTLRYGLLILMKYPEIEEKLHEEIDRVIGPSRIPAIKDRQEMPYMDAVVHEIQRF
ITLVPSNLPHEATRDTIFRGYLIPKGTVVVPTLDSVLYDNQEFPDPEKFKPEHFLNENGK
FKYSDYFKPFSTGKRVCAGEGLARMELFLLLCAILQHFNLKPLVDPKDIDLSPIHIGFGC
IPPRYKLCVIPRS

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P05181

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
11064188	Jackson CJ, Lamb DC, Kelly DE, Kelly SL: Bactericidal and inhibitory effects of azole antifungal compounds on Mycobacterium smegmatis. FEMS Microbiol Lett. 2000 Nov 15;192(2):159-62.
16543605	Pietila MP, Vohra PK, Sanyal B, Wengenack NL, Raghavakaimal S, Thomas CF Jr: Cloning and characterization of CYP51 from Mycobacterium avium. Am J Respir Cell Mol Biol. 2006 Aug;35(2):236-42. Epub 2006 Mar 16.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
20149798	Strushkevich N, Usanov SA, Park HW: Structural basis of human CYP51 inhibition by antifungal azoles. J Mol Biol. 2010 Apr 9;397(4):1067-78. Epub 2010 Feb 10.
20625155	Warrilow AG, Martel CM, Parker JE, Melo N, Lamb DC, Nes WD, Kelly DE, Kelly SL: Azole Binding Properties of Candida albicans Sterol 14-{alpha} Demethylase (CaCYP51). Antimicrob Agents Chemother. 2010 Jul 12.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X13296

# Drug_Target_1_GenBank_ID_Protein:
578119

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
ERG11

# Drug_Target_1_Gene_Sequence:
>1587 bp
ATGGCTATTGTTGAAACTGTCATTGATGGCATTAATTATTTTTTGTCCCTTAGTGTTACA
CAACAGATCAGTATATTATTAGGGGTTCCATTTGTTTACAACTTAGTATGGCAATATTTA
TATTCATTAAGAAAAGATAGAGCTCCATTAGTGTTTTATTGGATTCCTTGGTTTGGTTCT
GCAGCTTCATATGGTCAACAACCTTATGAATTTTTCGAATCATGTCGTCAAAAGTATGGT
GATGTATTTTCATTTATGTTATTAGGGAAAATTATGACGGTTTATTTAGGTCCAAAAGGT
CATGAATTTGTTTTTAATGCTAAATTATCTGATGTTTCTGCTGAAGATGCTTATAAACAT
TTAACTACTCCAGTTTTCGGTAAAGGGGTTATTTATGATTGTCCAAATTCCAGATTAATG
GAACAAAAAAAATTTGCTAAATTTGCTTTGACTACTGATTCATTTAAAAGATATGTTCCT
AAGATTAGAGAAGAAATTTTGAATTATTTTGTTACTGATGAAAGTTTCAAATTGAAAGAA
AAAACTCATGGGGTTGCCAATGTTATGAAAACTCAACCAGAAATTACTATTTTCACTGCT
TCAAGATCTTTATTTGGTGATGAAATGAGAAGAATTTTTGACCGTTCATTTGCTCAACTA
TATTCTGATTTAGATAAAGGTTTTACCCCTATTAATTTTGTTTTCCCTAATTTACCTTTA
CCTCATTATTGGAGACGTGATGCTGCTCAAAAGAAAATCTCTGCTACTTATATGAAAGAA
ATTAAACTGAGAAGAGAACGTGGTGATATTGATCCAAATCGTGATTTAATTGATTCCTTA
TTGATTCATTCAACTTATAAAGATGGTGTGAAAATGACTGATCAAGAAATTGCTAATCTT
TTAATTGGTATTCTTATGGGTGGTCAACATACTTCTGCTTCTACTTCTGCTTGGTTCTTG
TTACATTTAGGTGAAAAACCTCATTTACAAGATGTTATTTATCAAGAAGTTGTTGAATTA
TTGAAAGAAAAAGGTGGTGATTTGAATGATTTGACTTATGAAGATTTACAAAAATTACCA
TCAGTCAATAACACTATTAAGGAAACTCTCAGAATGCATATGCCATTACATTCTATTTTT
AGAAAAGTTACTAACCCATTAAGAATCCCTGAAACCAATTATATTGTTCCAAAAGGTCAT
TATGTTTTAGTTTCTCCAGGTTATGCTCATACTAGTGAAAGATATTTTGATAACCCTGAA
GATTTTGATCCAACTAGATGGGATACTGCTGCTGCCAAAGCTAATTCTGTTTCATTTAAC
TCTTCTGATGAAGTTGATTATGGGTTTGGGAAAGTTTCTAAAGGGGTTTCTTCACCTTAT
TTACCATTTGGTGGTGGTAGACATAGATGTATTGGGGAACAATTTGCTTATGTTCAATTA
GGAACCATTTTAACTACTTTTGTTTATAATTTAAGATGGACTATTGATGGTTATAAAGTG
CCTGACCCTGATTATAGTTCAATGGTGGTTTTACCTACTGAACCAGCAGAAATCATTTGG
GAAAAAAGAGAAACTTGTATGTTTTAA

# Drug_Target_1_General_Function:
Secondary metabolites biosynthesis, transport and catabolism

# Drug_Target_1_General_References:
2644625	Lai MH, Kirsch DR: Nucleotide sequence of cytochrome P450 L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans. Nucleic Acids Res. 1989 Jan 25;17(2):804.
7819160	Boscott PE, Grant GH: Modeling cytochrome P450 14 alpha demethylase (Candida albicans) from P450cam. J Mol Graph. 1994 Sep;12(3):185-92, 195.
9210671	White TC: The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans. Antimicrob Agents Chemother. 1997 Jul;41(7):1488-94.
9228762	Loffler J, Kelly SL, Hebart H, Schumacher U, Lass-Florl C, Einsele H: Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett. 1997 Jun 15;151(2):263-8.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
260

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
60676

# Drug_Target_1_Name:
Cytochrome P450 51

# Drug_Target_1_Number_of_Residues:
528

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00067	p450

# Drug_Target_1_Protein_Sequence:
>Cytochrome P450 51
MAIVETVIDGINYFLSLSVTQQISILLGVPFVYNLVWQYLYSLRKDRAPLVFYWIPWFGS
AASYGQQPYEFFESCRQKYGDVFSFMLLGKIMTVYLGPKGHEFVFNAKLSDVSAEDAYKH
LTTPVFGKGVIYDCPNSRLMEQKKFAKFALTTDSFKRYVPKIREEILNYFVTDESFKLKE
KTHGVANVMKTQPEITIFTASRSLFGDEMRRIFDRSFAQLYSDLDKGFTPINFVFPNLPL
PHYWRRDAAQKKISATYMKEIKSRRERGDIDPNRDLIDSLLIHSTYKDGVKMTDQEIANL
LIGILMGGQHTSASTSAWFLLHLGEKPHLQDVIYQEVVELLKEKGGDLNDLTYEDLQKLP
SVNNTIKETLRMHMPLHSIFRKVTNPLRIPETNYIVPKGHYVLVSPGYAHTSERYFDNPE
DFDPTRWDTAAAKANSVSFNSSDEVDYGFGKVSKGVSSPYLPFGGGRHRCIGEQFAYVQL
GTILTTFVYNLRWTIDGYKVPDPDYSSMVVLPTEPAEIIWEKRETCMF

# Drug_Target_1_Reaction:
obtusifoliol + 3 O2 + 3 NADPH + 3 H+ = 4alpha-methyl-5alpha-ergosta-8,14,24(28)-trien-3beta-ol + formate + 3 NADP+ + 4 H2O

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol

# Drug_Target_1_SwissProt_ID:
P10613

# Drug_Target_1_SwissProt_Name:
CP51_CANAL

# Drug_Target_1_Synonyms:
CYPLI
EC 1.14.13.70
Lanosterol 14-alpha demethylase
P450-14DM
P450-LIA1
Sterol 14- alpha demethylase

# Drug_Target_1_Theoretical_pI:
7.19

# Drug_Target_1_Transmembrane_Regions:
15-37; 50-69

#END_DRUGCARD DB01127
